Indication

Anaerobic pelvic cellulitis

Anaerobic pelvic cellulitis is a bacterial soft tissue infection of the pelvic connective tissues, broad ligaments, or retroperitoneal fascial planes, primarily affecting female patients. Read more about Anaerobic pelvic cellulitis

80 drugs 59 manufacturers

Advertisement

Drugs that treat it

Common Anaerobic pelvic cellulitis therapies.

Showing 1–9 of 80 drugs

CLINDAMYCIN HCL

CLINDAMYCIN SYSTEMIC·SEPSIS CAUSED BY ANAEROBIC BACTERIA·+19
Major Pharamceuticals
Filter & compare in the drug finder →Opens the drug finder with Anaerobic pelvic cellulitis preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Anaerobic pelvic cellulitis.

Anaerobic pelvic cellulitis is a bacterial soft tissue infection of the pelvic connective tissues, broad ligaments, or retroperitoneal fascial planes, primarily affecting female patients.

It classically arises as a complication of pelvic inflammatory disease, obstetric delivery, or gynecologic and intra-abdominal surgical procedures, where disruption of mucosal barriers allows opportunistic pathogens from the endogenous vaginal or colorectal microbiota to invade deeper retroperitoneal compartments.

Pathophysiologically driven by obligate or facultative anaerobic species—often in polymicrobial synergy with aerobic flora—the condition is characterized by diffuse, non-suppurative or indurated inflammation, vascular engorgement, and marked tissue edema.

Affected individuals typically present with lower abdominal or pelvic pain, uterine and adnexal tenderness, systemic fever, and leukocytosis, with the potential to progress to pelvic abscess formation or pelvic thrombophlebitis if untreated.

Personalize your experience

Follow Anaerobic pelvic cellulitis and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it